Crossmark

The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

Crossref DOI link: https://doi.org/10.1186/s12957-021-02410-3

Published Online: 2021-10-14

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Qiangyun

Zhang, Yixuan

Liu, Miaowen

Xu, Ruoxin

Yi, Fengming

Wei, Yiping

Zhu, Shuqiang

Zhang, Wenxiong https://orcid.org/0000-0003-2962-0847
License Information

Text and Data Mining valid from 2021-10-14

Version of Record valid from 2021-10-14
More Information

Article History

Received: 10 August 2021

Accepted: 25 September 2021

First Online: 14 October 2021

Declarations

:

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below